Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
Barclays Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $63
Barclays analyst Gena Wang maintains $Avidity Biosciences(RNA.US)$ with a buy rating, and maintains the target price at $63.According to TipRanks data, the analyst has a success rate of 46.7% and a
Avidity Biosciences to Participate in Upcoming Investor Conferences
Barclays Initiates Avidity Biosciences at Overweight
Barclays Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $63
Barclays analyst Gena Wang initiates coverage on $Avidity Biosciences(RNA.US)$ with a buy rating, and sets the target price at $63.According to TipRanks data, the analyst has a success rate of 46.7%
Analysts' Top Healthcare Picks: Addex Therapeutics (ADXN), Avidity Biosciences (RNA)